Fighting fire with fire: Phage potential for the treatment of E. coli o157 infection

Cristina Howard-Varona, Dean R. Vik, Natalie E. Solonenko, Yueh Fen Li, M. Consuelo Gazitua, Lauren Chittick, Jennifer K. Samiec, Aubrey E. Jensen, Paige Anderson, Adrian Howard-Varona, Anika A. Kinkhabwala, Stephen T. Abedon, Matthew Sullivan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hemolytic–uremic syndrome is a life-threating disease most often associated with Shiga toxin-producing microorganisms like Escherichia coli (STEC), including E. coli O157:H7. Shiga toxin is encoded by resident prophages present within this bacterium, and both its production and release depend on the induction of Shiga toxin-encoding prophages. Consequently, treatment of STEC infections tend to be largely supportive rather than antibacterial, in part due to concerns about exacerbating such prophage induction. Here we explore STEC O157:H7 prophage induction in vitro as it pertains to phage therapy—the application of bacteriophages as antibacterial agents to treat bacterial infections—to curtail prophage induction events, while also reducing STEC O157:H7 presence. We observed that cultures treated with strictly lytic phages, despite being lysed, produce substantially fewer Shiga toxin-encoding temperate-phage virions than untreated STEC controls. We therefore suggest that phage therapy could have utility as a prophylactic treatment of individuals suspected of having been recently exposed to STEC, especially if prophage induction and by extension Shiga toxin production is not exacerbated.

Original languageEnglish (US)
Article number101
JournalAntibiotics
Volume7
Issue number4
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Shiga Toxin
Escherichia coli Infections
Bacteriophages
Escherichia coli O157
Escherichia coli
Fires
Microorganisms
Virus Activation
Prophages
Therapeutics
Virion
Bacteria

Keywords

  • Antibiotic-resistant bacteria
  • Bacteriophage therapy
  • Lysogenic conversion
  • Phage therapy
  • Prophage induction
  • Read recruitment
  • Shiga toxin

ASJC Scopus subject areas

  • Microbiology
  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Howard-Varona, C., Vik, D. R., Solonenko, N. E., Li, Y. F., Gazitua, M. C., Chittick, L., ... Sullivan, M. (2018). Fighting fire with fire: Phage potential for the treatment of E. coli o157 infection. Antibiotics, 7(4), [101]. https://doi.org/10.3390/antibiotics7040101

Fighting fire with fire : Phage potential for the treatment of E. coli o157 infection. / Howard-Varona, Cristina; Vik, Dean R.; Solonenko, Natalie E.; Li, Yueh Fen; Gazitua, M. Consuelo; Chittick, Lauren; Samiec, Jennifer K.; Jensen, Aubrey E.; Anderson, Paige; Howard-Varona, Adrian; Kinkhabwala, Anika A.; Abedon, Stephen T.; Sullivan, Matthew.

In: Antibiotics, Vol. 7, No. 4, 101, 01.12.2018.

Research output: Contribution to journalArticle

Howard-Varona, C, Vik, DR, Solonenko, NE, Li, YF, Gazitua, MC, Chittick, L, Samiec, JK, Jensen, AE, Anderson, P, Howard-Varona, A, Kinkhabwala, AA, Abedon, ST & Sullivan, M 2018, 'Fighting fire with fire: Phage potential for the treatment of E. coli o157 infection', Antibiotics, vol. 7, no. 4, 101. https://doi.org/10.3390/antibiotics7040101
Howard-Varona C, Vik DR, Solonenko NE, Li YF, Gazitua MC, Chittick L et al. Fighting fire with fire: Phage potential for the treatment of E. coli o157 infection. Antibiotics. 2018 Dec 1;7(4). 101. https://doi.org/10.3390/antibiotics7040101
Howard-Varona, Cristina ; Vik, Dean R. ; Solonenko, Natalie E. ; Li, Yueh Fen ; Gazitua, M. Consuelo ; Chittick, Lauren ; Samiec, Jennifer K. ; Jensen, Aubrey E. ; Anderson, Paige ; Howard-Varona, Adrian ; Kinkhabwala, Anika A. ; Abedon, Stephen T. ; Sullivan, Matthew. / Fighting fire with fire : Phage potential for the treatment of E. coli o157 infection. In: Antibiotics. 2018 ; Vol. 7, No. 4.
@article{5145066f38f147b5b698fa456d9a1ff6,
title = "Fighting fire with fire: Phage potential for the treatment of E. coli o157 infection",
abstract = "Hemolytic–uremic syndrome is a life-threating disease most often associated with Shiga toxin-producing microorganisms like Escherichia coli (STEC), including E. coli O157:H7. Shiga toxin is encoded by resident prophages present within this bacterium, and both its production and release depend on the induction of Shiga toxin-encoding prophages. Consequently, treatment of STEC infections tend to be largely supportive rather than antibacterial, in part due to concerns about exacerbating such prophage induction. Here we explore STEC O157:H7 prophage induction in vitro as it pertains to phage therapy—the application of bacteriophages as antibacterial agents to treat bacterial infections—to curtail prophage induction events, while also reducing STEC O157:H7 presence. We observed that cultures treated with strictly lytic phages, despite being lysed, produce substantially fewer Shiga toxin-encoding temperate-phage virions than untreated STEC controls. We therefore suggest that phage therapy could have utility as a prophylactic treatment of individuals suspected of having been recently exposed to STEC, especially if prophage induction and by extension Shiga toxin production is not exacerbated.",
keywords = "Antibiotic-resistant bacteria, Bacteriophage therapy, Lysogenic conversion, Phage therapy, Prophage induction, Read recruitment, Shiga toxin",
author = "Cristina Howard-Varona and Vik, {Dean R.} and Solonenko, {Natalie E.} and Li, {Yueh Fen} and Gazitua, {M. Consuelo} and Lauren Chittick and Samiec, {Jennifer K.} and Jensen, {Aubrey E.} and Paige Anderson and Adrian Howard-Varona and Kinkhabwala, {Anika A.} and Abedon, {Stephen T.} and Matthew Sullivan",
year = "2018",
month = "12",
day = "1",
doi = "10.3390/antibiotics7040101",
language = "English (US)",
volume = "7",
journal = "Antibiotics",
issn = "2079-6382",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Fighting fire with fire

T2 - Phage potential for the treatment of E. coli o157 infection

AU - Howard-Varona, Cristina

AU - Vik, Dean R.

AU - Solonenko, Natalie E.

AU - Li, Yueh Fen

AU - Gazitua, M. Consuelo

AU - Chittick, Lauren

AU - Samiec, Jennifer K.

AU - Jensen, Aubrey E.

AU - Anderson, Paige

AU - Howard-Varona, Adrian

AU - Kinkhabwala, Anika A.

AU - Abedon, Stephen T.

AU - Sullivan, Matthew

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Hemolytic–uremic syndrome is a life-threating disease most often associated with Shiga toxin-producing microorganisms like Escherichia coli (STEC), including E. coli O157:H7. Shiga toxin is encoded by resident prophages present within this bacterium, and both its production and release depend on the induction of Shiga toxin-encoding prophages. Consequently, treatment of STEC infections tend to be largely supportive rather than antibacterial, in part due to concerns about exacerbating such prophage induction. Here we explore STEC O157:H7 prophage induction in vitro as it pertains to phage therapy—the application of bacteriophages as antibacterial agents to treat bacterial infections—to curtail prophage induction events, while also reducing STEC O157:H7 presence. We observed that cultures treated with strictly lytic phages, despite being lysed, produce substantially fewer Shiga toxin-encoding temperate-phage virions than untreated STEC controls. We therefore suggest that phage therapy could have utility as a prophylactic treatment of individuals suspected of having been recently exposed to STEC, especially if prophage induction and by extension Shiga toxin production is not exacerbated.

AB - Hemolytic–uremic syndrome is a life-threating disease most often associated with Shiga toxin-producing microorganisms like Escherichia coli (STEC), including E. coli O157:H7. Shiga toxin is encoded by resident prophages present within this bacterium, and both its production and release depend on the induction of Shiga toxin-encoding prophages. Consequently, treatment of STEC infections tend to be largely supportive rather than antibacterial, in part due to concerns about exacerbating such prophage induction. Here we explore STEC O157:H7 prophage induction in vitro as it pertains to phage therapy—the application of bacteriophages as antibacterial agents to treat bacterial infections—to curtail prophage induction events, while also reducing STEC O157:H7 presence. We observed that cultures treated with strictly lytic phages, despite being lysed, produce substantially fewer Shiga toxin-encoding temperate-phage virions than untreated STEC controls. We therefore suggest that phage therapy could have utility as a prophylactic treatment of individuals suspected of having been recently exposed to STEC, especially if prophage induction and by extension Shiga toxin production is not exacerbated.

KW - Antibiotic-resistant bacteria

KW - Bacteriophage therapy

KW - Lysogenic conversion

KW - Phage therapy

KW - Prophage induction

KW - Read recruitment

KW - Shiga toxin

UR - http://www.scopus.com/inward/record.url?scp=85057190200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057190200&partnerID=8YFLogxK

U2 - 10.3390/antibiotics7040101

DO - 10.3390/antibiotics7040101

M3 - Article

AN - SCOPUS:85057190200

VL - 7

JO - Antibiotics

JF - Antibiotics

SN - 2079-6382

IS - 4

M1 - 101

ER -